ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

7 links0 made here, not in the record14 judgments2 judges (the rules as one: Rule based)5 record changes seen
Model not recordedRule basedRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06772623Study to Evaluate AdverseEvents and Efficacy ofIntravenous (IV)Telisotuzumab Adizutecan inCombination With a PD-1Immune Checkpoint Inhibitorin Adult Participants WithAbbViePhase 1/Phase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 29 · ClinicalTrials.gov record · Version of 2026-09-29Oct 5 · ClinicalTrials.gov record · Version of 2026-10-05Oct 20 · ClinicalTrials.gov record · Version of 2026-10-20Oct 27 · ClinicalTrials.gov record · Version of 2026-10-27Nov 19 · ClinicalTrials.gov record · Version of 2026-11-19Version of 2026-11-19CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSTelisotuzumab adizutecanIntervention entry›Nov 1 · A model not recorded · TestedNov 18 · Rule based · TestedTestedBudigalimabIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackgroundPembrolizumabIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · TestedBackgroundCarboplatinIntervention entry›Nov 1 · A model not recorded · ComparatorNov 18 · Rule based · TestedComparatorPemetrexedIntervention entry›Nov 1 · A model not recorded · ComparatorNov 18 · Rule based · TestedComparatorCisplatinIntervention entry›Nov 1 · A model not recorded · ComparatorNov 18 · Rule based · TestedComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Telisotuzumab adizutecan

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Telisotuzumab Adizutecan”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Sep 29The record itselfClinicalTrials.gov recordVersion of 2026-09-29Record change
Oct 5The record itselfClinicalTrials.gov recordVersion of 2026-10-05Record change
Oct 20The record itselfClinicalTrials.gov recordVersion of 2026-10-20Record change
Oct 27The record itselfClinicalTrials.gov recordVersion of 2026-10-27Record change
Nov 1Telisotuzumab adizutecanA model not recordedTestedCurrent
Nov 1BudigalimabA model not recordedBackgroundCurrent
Nov 1PembrolizumabA model not recordedBackgroundCurrent
Nov 1CarboplatinA model not recordedComparatorCurrent
Nov 1PemetrexedA model not recordedComparatorCurrent
Nov 1CisplatinA model not recordedComparatorCurrent
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 18Telisotuzumab adizutecanRule based · role ruleTestedAgrees
Nov 18BudigalimabRule based · role ruleBackgroundAgrees
Nov 18PembrolizumabRule based · role ruleTestedOverridden
Nov 18CarboplatinRule based · role ruleTestedOverridden
Nov 18PemetrexedRule based · role ruleTestedOverridden
Nov 18CisplatinRule based · role ruleTestedOverridden
Nov 19The record itselfClinicalTrials.gov recordVersion of 2026-11-19Record change
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.